Penn Bioethics Seminar Series (PBS): Nir Eyal, DPhil
12:00pm - 1:00pm • via Zoom
2021-03-30 12:00:00 2021-03-30 13:00:00 America/New_York Penn Bioethics Seminar Series (PBS): Nir Eyal, DPhil Why human challenge trials of COVID-19 are (still) both important and legitimate Nir Eyal, DPhil, Henry Rutgers Professor of Bioethics, School of Public Health and Philosophy Department and Director, Center for Population-Level Bioethics, Rutgers University Registration required for all events. Meeting link will be provided automatically upon sign-up. Sign up here: https://zoom.us/meeting/register/tJYkdOGoqz8pHtxA3m0VLTrp4rgSVsPb-3Ea Abstract: The UK is starting SARS-CoV-2 human challenge trials. America has so far resisted them, mainly based on ethical objections. This talk will relay the important unanswered questions about both authorized and future COVID vaccines that challenge trials could help us answer, and explain why the ethical objections were and remain misguided. Nir Eyal is the inaugural Henry Rutgers Professor of Bioethics at Rutgers University. He founded and directs Rutgers’s Center for Population-Level Bioethics, with appointments at the School of Public Health and the Department of Philosophy. Dr. Eyal’s work covers many areas of research ethics and population-level bioethics, including (relevantly to this talk) ethics in emerging infection vaccine trials, ethics of high-risk trials, and the ethics of disaster response. Eyal’s work appeared in Science, PNAS, NEJM, Lancet, BMJ, and the leading bioethics venues. He is a coauthor of a WHO report, and has co-edited eight volumes and journal symposia, as well as the Oxford University Press series Population Level Bioethics. Eyal is the recipient of multiple awards from NIH, Wellcome, NSF, and other sources. He was the lead author of the first peer-reviewed article in support of challenge trials for novel Coronavirus vaccine candidates. Please email mary.pham@pennmedicine.upenn.edu to be added to the listserv to receive passwords and announcements. via Zoom Penn Medical EthicsWhy human challenge trials of COVID-19 are (still) both important and legitimate
Nir Eyal, DPhil, Henry Rutgers Professor of Bioethics, School of Public Health and Philosophy Department and Director, Center for Population-Level Bioethics, Rutgers University
Registration required for all events.
Meeting link will be provided automatically upon sign-up.
Sign up here: https://zoom.us/meeting/register/tJYkdOGoqz8pHtxA3m0VLTrp4rgSVsPb-3Ea
Abstract: The UK is starting SARS-CoV-2 human challenge trials. America has so far resisted them, mainly based on ethical objections. This talk will relay the important unanswered questions about both authorized and future COVID vaccines that challenge trials could help us answer, and explain why the ethical objections were and remain misguided.
Nir Eyal is the inaugural Henry Rutgers Professor of Bioethics at Rutgers University. He founded and directs Rutgers’s Center for Population-Level Bioethics, with appointments at the School of Public Health and the Department of Philosophy. Dr. Eyal’s work covers many areas of research ethics and population-level bioethics, including (relevantly to this talk) ethics in emerging infection vaccine trials, ethics of high-risk trials, and the ethics of disaster response. Eyal’s work appeared in Science, PNAS, NEJM, Lancet, BMJ, and the leading bioethics venues. He is a coauthor of a WHO report, and has co-edited eight volumes and journal symposia, as well as the Oxford University Press series Population Level Bioethics. Eyal is the recipient of multiple awards from NIH, Wellcome, NSF, and other sources. He was the lead author of the first peer-reviewed article in support of challenge trials for novel Coronavirus vaccine candidates.
Please email mary.pham@pennmedicine.upenn.edu to be added to the listserv to receive passwords and announcements.